The purpose of the study is to evaluate how well these treatments work and how safe they are for patients with these infections. Participants in the study will receive one of the treatment combinations or a placebo, and their progress will be monitored over a period of time. The study will involve regular visits to the clinic for check-ups and assessments to see how the infection is responding to the treatment. The goal is to find out which treatment is most effective in curing the infection and preventing it from coming back.

Throughout the study, participants will be closely observed to ensure their safety and to monitor any side effects that may occur. The study aims to provide valuable information that could help improve the treatment of these types of infections in the future. By comparing the different treatment options, researchers hope to identify the best approach for managing cUTI and AP, ultimately leading to better outcomes for patients.

The purpose of this research is to determine how well oral tebipenem pivoxil works compared to intravenous imipenem-cilastatin in treating these urinary tract infections. The study will measure whether the infections are cured and if the bacteria causing the infections are eliminated. The medications will be given to adult patients who are in the hospital.

During the study, patients will receive treatment for up to 10 days. The study team will monitor patients’ symptoms and take urine samples to check if the infection is responding to treatment. They will also check for any side effects from the medications. After the treatment period ends, patients will have follow-up visits to ensure the infection has been properly treated.

Participants in the study will be randomly assigned to receive either andexanet alfa or the standard treatment, which may include a placebo. The study will monitor the effectiveness of andexanet alfa in controlling bleeding during surgery and will also track changes in the activity of the Factor Xa inhibitors from the start of the surgery to two hours afterward. The study aims to provide valuable information on how well andexanet alfa works in real-world surgical settings.

The trial will involve a series of steps, including the administration of the treatment and careful monitoring of the patient’s condition during and after the surgery. The study is expected to continue until November 2026, with recruitment starting in December 2023. This research is important for improving the safety and effectiveness of surgeries for patients who are on Factor Xa inhibitors and need urgent medical attention.

The purpose of the study is to evaluate how well these medications work in treating moderate or severe diabetic foot infections. Participants will be randomly assigned to receive either the new medications, Contezolid Acefosamil and Contezolid, or the existing medication, Linezolid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for a period of up to 28 days, during which the participants’ health and response to the treatment will be closely monitored by the study team.

Throughout the study, the safety and tolerability of the medications will be assessed, meaning the researchers will check for any side effects or adverse reactions. The main goal is to see if the new medications are as effective or more effective than Linezolid in treating the infections. Participants will have regular check-ups and assessments to track their progress and the effectiveness of the treatment. The study aims to provide valuable information that could lead to improved treatment options for people with diabetic foot infections.